A Phase 1b/2 Study to Evaluate the Safety and Efficacy of AMG 655 or AMG 479 in Combination With Gemcitabine as First-Line Therapy for Metastatic Pancreatic Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Survival
6 months
No
MD
Study Director
Amgen
United States: Food and Drug Administration
20060323
NCT00630552
June 2007
April 2012
Name | Location |
---|---|
Research Site | Anaheim, California |
Research Site | Boca Raton, Florida |
Research Site | Albany, Georgia |
Research Site | Arlington Heights, Illinois |
Research Site | Baltimore, Maryland |
Research Site | Beverly, Massachusetts |
Research Site | Branson, Missouri |
Research Site | Las Vegas, Nevada |
Research Site | Albany, New York |
Research Site | Asheville, North Carolina |
Research Site | Akron, Ohio |
Research Site | Bend, Oregon |
Research Site | Allentown, Pennsylvania |
Research Site | Pawtucket, Rhode Island |
Research Site | Charleston, South Carolina |
Research Site | Abilene, Texas |
Research Site | Auburn, Washington |